Juan Morote

List of Publications by Citations

236 papers	4,292 citations	35 h-index	58 g-index
264 ext. papers	4,953 ext. citations	3.7 avg, IF	4.88 L-index

#	Paper	IF	Citations
236	Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. *Lancet, The*, **2012**, 379, 39-46	40	612
235	Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. *Journal of Urology*, **2007**, 178, 1290-5	2.5	199
234	Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. *Journal of Clinical Oncology*, **2013**, 31, 3800-6	2.2	145
233	Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. *Urology*, **2007**, 69, 500-4	1.6	127
232	Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients. *European Journal of Nuclear Medicine and Molecular Imaging*, **1999**, 26, 625-32	8.8	119
231	The reproducibility and predictive value on outcome of renal biopsies from expanded criteria donors. *Kidney International*, **2014**, 85, 1161-8	9.9	97
230	Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. *BJU International*, **2011**, 108, 24-30	5.6	90
229	Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. *Journal of Urology*, **2006**, 175, 1679-83; discussion 1683	2.5	80
228	Effect of inflammation and benign prostatic enlargement on total and percent free serum prostatic specific antigen. *European Urology*, **2000**, 37, 537-40	10.2	78
227	PTOV1 enables the nuclear translocation and mitogenic activity of flotillin-1, a major protein of lipid rafts. *Molecular and Cellular Biology*, **2005**, 25, 1900-11	4.8	77
226	Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. *Histology and Histopathology*, **2006**, 21, 857-65	1.4	72
225	Identification and genotyping of human papillomavirus in a Spanish cohort of penile squamous cell carcinomas: correlation with pathologic subtypes, p16(INK4a) expression, and prognosis. *Journal of the American Academy of Dermatology*, **2013**, 68, 73-82	4.5	68
224	Clinical Efficacy of Bone Alkaline Phosphatase and Prostate Specific Antigen in the Diagnosis of Bone Metastasis in Prostate Cancer. *Journal of Urology*, **1996**, 155, 1348-1351	2.5	59
223	Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer. *Oncotarget*, **2017**, 8, 4960-4976	3.3	58
222	HAVCR/KIM-1 activates the IL-6/STAT-3 pathway in clear cell renal cell carcinoma and determines tumor progression and patient outcome. *Cancer Research*, **2014**, 74, 1416-28	10.1	56
221	Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer. *International Journal of Cancer*, **1999**, 84, 421-5	7.5	56
220	Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. *Urologia Internationalis*, **2006**, 77, 135-8	1.9	55

219	PTOV1, a novel protein overexpressed in prostate cancer containing a new class of protein homology blocks. *Oncogene*, **2001**, 20, 1455-64	9.2	54
218	Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. *European Urology*, **2003**, 44, 661-5	10.2	49
217	Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. *Cancer*, **1992**, 70, 1974-9	6.4	48
216	PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine. *Prostate*, **2010**, 70, 1760-7	4.2	47
215	Comparison of Percent Free Prostate Specific Antigen and Prostate Specific Antigen Density as Methods to Enhance Prostate Specific Antigen Specificity in Early Prostate Cancer Detection in Men With Normal Rectal Examination and Prostate Specific Antigen Between 4.1 and 10 ng./ml.. *Journal of Urology*, **1997**, 158, 502-504	2.5	47
214	PTOV1 expression predicts prostate cancer in men with isolated high-grade prostatic intraepithelial neoplasia in needle biopsy. *Clinical Cancer Research*, **2008**, 14, 2617-22	12.9	45
213	Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer. *International Journal of Cancer*, **2004**, 108, 877-81	7.5	45
212	Metabolic syndrome increases the risk of aggressive prostate cancer detection. *BJU International*, **2013**, 111, 1031-6	5.6	43
211	Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy. *BJU International*, **2009**, 103, 332-5; discussion 335	5.6	43
210	Value of routine transition zone biopsies in patients undergoing ultrasound-guided sextant biopsies for the first time. *European Urology*, **1999**, 35, 294-7	10.2	42
209	Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients. *British Journal of Cancer*, **2015**, 112, 468-74	8.7	40
208	PTOV-1, a novel protein overexpressed in prostate cancer, shuttles between the cytoplasm and the nucleus and promotes entry into the S phase of the cell division cycle. *American Journal of Pathology*, **2003**, 162, 897-905	5.8	40
207	The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy. *Journal of Urology*, **2015**, 193, 1963-9	2.5	39
206	The present and future of prostate cancer urine biomarkers. *International Journal of Molecular Sciences*, **2013**, 14, 12620-49	6.3	39
205	The relationship between daily calcium intake and bone mineral density in men with prostate cancer. *BJU International*, **2007**, 99, 812-5; discussion 815-6	5.6	39
204	A three-gene panel on urine increases PSA specificity in the detection of prostate cancer. *Prostate*, **2011**, 71, 1736-45	4.2	37
203	The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness. *BJU International*, **2009**, 104, 486-9	5.6	36
202	Variant forms of bladder cancer: basic considerations on treatment approaches. *Current Oncology Reports*, **2011**, 13, 216-21	6.3	35

201	Antiproliferative and apoptotic effects of the herbal agent Pygeum africanum on cultured prostate stromal cells from patients with benign prostatic hyperplasia (BPH). *Prostate*, **2010**, 70, 1044-53	4.2	34
200	Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR. *BJU International*, **2010**, 105, 202-7	5.6	32
199	Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. *BJU International*, **2009**, 104, 1637-40	5.6	31
198	Testosterone measurement in patients with prostate cancer. *European Urology*, **2010**, 58, 65-74	10.2	31
197	Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study. *British Journal of Cancer*, **2013**, 108, 2565-72	8.7	28
196	Hepatitis A virus receptor blocks cell differentiation and is overexpressed in clear cell renal cell carcinoma. *Kidney International*, **2004**, 65, 1761-73	9.9	28
195	Identification of multipotent mesenchymal stromal cells in the reactive stroma of a prostate cancer xenograft by side population analysis. *Experimental Cell Research*, **2009**, 315, 3004-13	4.2	27
194	Prediction of prostate volume based on total and free serum prostate-specific antigen: is it reliable?. *European Urology*, **2000**, 38, 91-5	10.2	27
193	Effects of holmium laser enucleation of the prostate on sexual function. *Journal of Endourology*, **2015**, 29, 332-9	2.7	26
192	Altered transcription factor E3 expression in unclassified adult renal cell carcinoma indicates adverse pathological features and poor outcome. *BJU International*, **2011**, 108, E71-6	5.6	26
191	Improved prediction of biochemical recurrence after radical prostatectomy by genetic polymorphisms. *Journal of Urology*, **2010**, 184, 506-11	2.5	25
190	Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk. *BJU International*, **2010**, 105, 481-4	5.6	24
189	Behavior of the PCA3 gene in the urine of men with high grade prostatic intraepithelial neoplasia. *World Journal of Urology*, **2010**, 28, 677-80	4	24
188	Expression of androgen, oestrogen alpha and beta, and progesterone receptors in the canine prostate: differences between normal, inflamed, hyperplastic and neoplastic glands. *Journal of Comparative Pathology*, **2007**, 136, 1-8	1	23
187	Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients. *Urologia Internationalis*, **2013**, 90, 41-4	1.9	22
186	Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. *Journal of Urology*, **2017**, 198, 817-823	2.5	21
185	Hepatitis A virus cellular receptor 1/kidney injury molecule-1 is a susceptibility gene for clear cell renal cell carcinoma and hepatitis A virus cellular receptor/kidney injury molecule-1 ectodomain shedding a predictive biomarker of tumour progression. *European Journal of Cancer*, **2013**, 49, 2034-47	7.5	21
184	Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness. *International Journal of Molecular Sciences*, **2014**, 15, 13615-23	6.3	21

183	PTOV1 is overexpressed in human high-grade malignant tumors. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2011**, 458, 323-30	5.1	21
182	Gastric cancer in augmentation gastrocystoplasty. *Urologia Internationalis*, **2005**, 74, 368-70	1.9	20
181	Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. *Cancer Research*, **2020**, 80, 4476-4486	10.1	20
180	Prostate carcinoma staging: Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen. *Cancer*, **1996**, 78, 2374-2378	6.4	18
179	Maximal testosterone suppression in prostate cancer--free vs total testosterone. *Urology*, **2014**, 83, 1217-22	1.7	16
178	Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice. *BJU International*, **2014**, 113, E164-77	5.6	16
177	Re: Nicolas Mottet, Joaquim Bellmunt, Erik Briers, et al. EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. European Association of Urology; 2017. http://uroweb.org/guideline/prostate-cancer: How to Assess the Efficacy of Medical Castration. *European Urology*, **2018**, 73, e134-e135	10.2	15
176	Sedentarism and overweight as risk factors for the detection of prostate cancer and its aggressivenes. *Actas Urológicas Españolas*, **2014**, 38, 232-7	0.7	15
175	Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study. *British Journal of Cancer*, **2013**, 109, 121-30	8.7	15
174	Usefulness of prostate-specific antigen nadir as predictor of androgen-independent progression of metastatic prostate cancer. *International Journal of Biological Markers*, **2005**, 20, 209-16	2.8	15
173	Clinical Significance of Proliferative Inflammatory Atrophy in Negative Prostatic Biopsies. *Prostate*, **2016**, 76, 1501-1506	4.2	14
172	Genetic predisposition to early recurrence in clinically localized prostate cancer. *BJU International*, **2013**, 111, 549-58	5.6	14
171	Identification of somatic gene mutations in penile squamous cell carcinoma. *Genes Chromosomes and Cancer*, **2015**, 54, 629-37	5	14
170	Preoperative prediction of pathologically insignificant prostate cancer in radical prostatectomy specimens: the role of prostate volume and the number of positive cores. *Urologia Internationalis*, **2010**, 84, 153-8	1.9	14
169	Measurement of free PSA in the diagnosis and staging of prostate cancer. *International Journal of Cancer*, **1997**, 71, 756-9	7.5	14
168	Over-expression of epidermal growth factor receptor and c-erbB2/neu but not of int-2 genes in benign prostatic hyperplasia by means of semi-quantitative PCR. *International Journal of Cancer*, **1998**, 76, 464-7	7.5	14
167	Intraindividual variations of total and percent free serum prostatic-specific antigen levels in patients with normal digital rectal examination. *European Urology*, **1999**, 36, 111-5	10.2	14
166	Who Benefits from Multiparametric Magnetic Resonance Imaging After Suspicion of Prostate Cancer?. *European Urology Oncology*, **2019**, 2, 664-669	6.7	13

165	Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer. *European Urology*, **2014**, 66, 655-63	10.2	13
164	Androgen-Deprivation Therapy in Prostate Cancer: A European Expert Panel Review. *European Urology Supplements*, **2010**, 9, 675-691	0.9	13
163	The percentage of free prostatic-specific antigen is also useful in men with normal digital rectal examination and serum prostatic-specific antigen between 10.1 and 20 ng/ml. *European Urology*, **2002**, 42, 333-7	10.2	13
162	Urinary biomarkers for the detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. *Prostate*, **2015**, 75, 1102-13	4.2	12
161	Behavior of chemiluminescent assays to measure serum testosterone during androgen deprivation therapy. *International Journal of Urology*, **2016**, 23, 957-958	2.3	12
160	Simultaneous treatment with statins and aspirin reduces the risk of prostate cancer detection and tumorigenic properties in prostate cancer cell lines. *BioMed Research International*, **2015**, 2015, 762178	3	12
159	Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues. *BioMed Research International*, **2013**, 2013, 283635	3	12
158	Use of percent free prostate-specific antigen as a predictor of the pathological features of clinically localized prostate cancer. *European Urology*, **2000**, 38, 225-9	10.2	12
157	Effect of high-grade prostatic intraepithelial neoplasia on total and percent free serum prostatic-specific antigen. *European Urology*, **2000**, 37, 456-9	10.2	12
156	Cognitive Function in Patients With Prostate Cancer Receiving Luteinizing Hormone-Releasing Hormone Analogues: A Prospective, Observational, Multicenter Study. *International Journal of Radiation Oncology Biology Physics*, **2017**, 98, 590-594	4	11
155	Clinical significance of proliferative inflammatory atrophy finding in prostatic biopsies. *Prostate*, **2015**, 75, 1669-75	4.2	11
154	Prostate cancer in Spain: from guidelines to clinical practice. *BJU International*, **2011**, 108, 61-6	5.6	11
153	M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **1996**, 19, 344-8	2.7	11
152	Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope. *Cancer Treatment Reviews*, **2016**, 50, 208-216	14.4	11
151	Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer. *Critical Reviews in Oncology/Hematology*, **2016**, 100, 127-36	7	10
150	Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition. *Actas Urológicas Españolas*, **2013**, 37, 292-304	0.7	10
149	The free-to-total serum prostatic specific antigen ratio as a predictor of the pathological features of prostate cancer. *BJU International*, **1999**, 83, 1003-6	5.6	10
148	Effect of denosumab on prolonging bone-metastasis-free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics.. *Journal of Clinical Oncology*, **2012**, 30, 6-6	2.2	10

147	Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells. *Oncotarget*, **2017**, 8, 59165-59180	3.3	10
146	Comparison of perioperative outcomes and complications of robot assisted radical cystectomy with extracorporeal vs intracorporeal urinary diversion. *Actas Urológicas Españolas*, **2019**, 43, 277-283	0.7	10
145	Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy. *Clinical Genitourinary Cancer*, **2018**, 16, e491-e496	3.3	10
144	Diagnostic accuracy of prostate health index to identify aggressive prostate cancer. An Institutional validation study. *Actas Urológicas Españolas*, **2016**, 40, 378-85	0.7	9
143	Measurement of serum testosterone during androgenic suppression in patients with prostate cancer: A systematic review. *Actas Urológicas Españolas*, **2016**, 40, 477-84	0.7	9
142	Immunolocalization of androgen receptors, estrogen alpha receptors, and estrogen beta receptors in experimentally induced canine prostatic hyperplasia. *Journal of Andrology*, **2009**, 30, 240-7		9
141	Behavior of free Testosterone in Patients with Prostate Cancer on Androgen Deprivation Therapy. *International Journal of Biological Markers*, **2005**, 20, 119-122	2.8	9
140	Increase of bone alkaline phosphatase after androgen deprivation therapy in patients with prostate cancer. *Urology*, **2002**, 59, 277-80	1.6	9
139	Low-dose statin treatment increases prostate cancer aggressiveness. *Oncotarget*, **2018**, 9, 1494-1504	3.3	9
138	Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. *Journal of Urology*, **1996**, 155, 1348-51	2.5	9
137	Behavior of total and free serum testosterone as a predictor for the risk of prostate cancer and its aggressiveness. *Actas Urológicas Españolas*, **2015**, 39, 573-81	0.7	8
136	The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor. *Cancer Treatment Reviews*, **2020**, 86, 102000	14.4	8
135	Free Testosterone During Androgen Deprivation Therapy Predicts Castration-Resistant Progression Better Than Total Testosterone. *Prostate*, **2017**, 77, 114-120	4.2	8
134	Systematic review of renal carcinoma prognostic factors. *Actas Urológicas Españolas*, **2017**, 41, 215-225	0.7	8
133	Identification, characterization and expression of novel Sex Hormone Binding Globulin alternative first exons in the human prostate. *BMC Molecular Biology*, **2009**, 10, 59	4.5	8
132	Is there a relationship between prostate volume and Gleason score?. *BJU International*, **2008**, 102, 563-5	5.6	8
131	Influence of high-grade prostatic intra-epithelial neoplasia on total and percentage free serum prostatic specific antigen. *BJU International*, **1999**, 84, 657-60	5.6	8
130	Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: a Spanish expanded access trial. *Orphanet Journal of Rare Diseases*, **2016**, 11, 128	4.2	8

129	Prostatic-specific antigen density behavior according to multiparametric magnetic resonance imaging result. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 410-417	2.8	7
128	Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer. *Scandinavian Journal of Urology*, **2016**, 50, 425-428	1.6	7
127	Extensive emphysematous pyelonephritis in a renal allograft: case report and review of literature. *Transplant Infectious Disease*, **2014**, 16, 642-7	2.7	7
126	Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed?. *BJU International*, **2015**, 115, 364-72	5.6	7
125	Clinical significance of proliferative inflammatory atrophy in prostate biopsy. *Actas Urológicas Españolas*, **2014**, 38, 122-6	0.7	7
124	Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy?. *Clinical and Translational Oncology*, **2014**, 16, 102-6	3.6	7
123	Androgen-independent basal cell re-epithelialization, c-erbB-2 mRNA expression and androgen-dependent EGFr mRNA expression in benign prostatic hyperplasia explant cultures treated with finasteride. *International Journal of Cancer*, **1998**, 76, 519-22	7.5	7
122	Effect of androgen deprivation therapy in the thyroid function test of patients with prostate cancer. *Anti-Cancer Drugs*, **2005**, 16, 863-6	2.4	7
121	Under-expression of CK2β subunit in ccRCC represents a complementary biomarker of p-STAT3 Ser727 that correlates with patient survival. *Oncotarget*, **2018**, 9, 5736-5751	3.3	7
120	Micronuclei frequency in urothelial cells of bladder cancer patients, as a biomarker of prognosis. *Environmental and Molecular Mutagenesis*, **2019**, 60, 168-173	3.2	7
119	(Bora), Which Promotes Plk1 Activation by Aurora A, Has an Oncogenic Role in Ovarian Cancer. *Cancers*, **2020**, 12,	6.6	7
118	Cognitive function in patients on androgen suppression: A prospective, multicentric study. *Actas Urológicas Españolas*, **2018**, 42, 114-120	0.7	6
117	Hormonal changes after localized prostate cancer treatment. Comparison between external beam radiation therapy and radical prostatectomy. *Actas Urológicas Españolas*, **2016**, 40, 549-555	0.7	6
116	Re: Marko Babjuk, Willem Oosterlinck, Richard Sylvester, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008;54:303-14. *European Urology*, **2009**, 55, e15-6; author reply e17-8	10.2	6
115	Evidence-based consensus recommendations to improve the quality of life in prostate cancer treatment. *Clinical and Translational Oncology*, **2010**, 12, 346-55	3.6	6
114	A transcriptional signature associated with the onset of benign prostate hyperplasia in a canine model. *Prostate*, **2010**, 70, 1402-12	4.2	6
113	The role of STAT3 protein as a prognostic factor in the clear cell renal carcinoma. Systematic review. *Actas Urológicas Españolas*, **2019**, 43, 118-123	0.7	6
112	Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml. *Journal of Urology*, **1997**, 158, 502-4	2.5	6

111	siRNA-silencing of CD40 attenuates unilateral ureteral obstruction-induced kidney injury in mice. *PLoS ONE*, **2019**, 14, e0215232	3.7	5
110	Utility of the RENAL index -Radius; Exophytic/endophytic; Nearness to sinus; Anterior/posterior; Location relative to polar lines- in the management of renal masses. *Actas Urológicas Españolas*, **2016**, 40, 601-607	0.7	5
109	Ultrastructural changes in prostate cells during hormone-induced canine prostatic hyperplasia. *Ultrastructural Pathology*, **2006**, 30, 435-42	1.3	5
108	Case report: retroperitoneal fibrosis simulating local relapse of sarcomatoid renal cell carcinoma. *International Urology and Nephrology*, **2006**, 38, 463-5	2.3	5
107	Impact of immune-related adverse events on survival in patients with metastastic urothelial carcinoma treated with immune-checkpoint inhibitors.. *Journal of Clinical Oncology*, **2019**, 37, 4531-4531	2.2	5
106	The role of prostate tumor overexpressed 1 in cancer progression. *Oncotarget*, **2017**, 8, 12451-12471	3.3	5
105	Individual variations of total and percent free serum prostatic specific antigen: could they change the indication of prostatic biopsy?. *Oncology Reports*, **1999**, 6, 887-90	3.5	5
104	Preoperative magnetic resonance imaging in predicting early continence recovery after robotic radical prostatectomy. *Actas Urológicas Españolas*, **2019**, 43, 137-142	0.7	5
103	How to implement magnetic resonance imaging before prostate biopsy in clinical practice: nomograms for saving biopsies. *World Journal of Urology*, **2020**, 38, 1481-1491	4	5
102	Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy. *International Journal of Biological Markers*, **2005**, 20, 119-22	2.8	5
101	Comparison of Outcomes between Standard and Palliative Management for High Grade Non-Muscle Invasive Bladder Cancer in Patients Older than 85 Years. *Urologia Internationalis*, **2019**, 102, 277-283	1.9	4
100	Current significance of the finding of high grade prostatic intraepithelial neoplasia in the prostate biopsy. *Actas Urológicas Españolas*, **2014**, 38, 270-5	0.7	4
99	Metabolic syndrome in patients with prostate cancer undergoing androgen suppression. *Actas Urológicas Españolas*, **2014**, 38, 285-9	0.7	4
98	Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition. *Actas Urológicas Españolas (English Edition)*, **2013**, 37, 292-304	0.1	4
97	33% radius evaluation to assess bone mineral density in prostate cancer patients. *World Journal of Urology*, **2011**, 29, 815-9	4	4
96	Correlation between the biopsies in marginal donor kidneys for transplantation: is it necessary to biopsy both kidneys?. *Transplantation Proceedings*, **2006**, 38, 1270-3	1.1	4
95	Value of Percent Free Prostate-Specific Antigen for the Prediction of Pathological Stage in Men with Clinically Localized Prostate Cancer. *International Journal of Biological Markers*, **2002**, 17, 239-243	2.8	4
94	Elevated serum PSA and acute bacterial prostatitis. *Urology*, **1990**, 35, 373	1.6	4

93	Bone marrow prostatic specific antigen and prostatic acid phosphatase levels: are they helpful in staging prostatic cancer?. *Journal of Urology*, **1987**, 137, 891-3	2.5	4
92	A Randomised Controlled Trial to Assess the Benefit of Posterior Rhabdosphincter Reconstruction in Early Urinary Continence Recovery after Robot-assisted Radical Prostatectomy. *European Urology Oncology*, **2021**,	6.7	4
91	Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation Therapy. *European Urology Focus*, **2017**, 3, 470-479	5.1	3
90	Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients. *Journal of Biomedical Science*, **2017**, 24, 81	13.3	3
89	Current status of tissue engineering applied to bladder reconstruction in humans. *Actas Urológicas Españolas*, **2018**, 42, 435-441	0.7	3
88	A systematic review of methods for quantifying serum testosterone in patients with prostate cancer who underwent castration. *Actas Urológicas Españolas*, **2018**, 42, 86-93	0.7	3
87	Bone mass behavior after 1 year of different treatment strategies in prostate cancer patients subjected to androgen deprivation therapy. *Rheumatology International*, **2014**, 34, 1419-25	3.6	3
86	Role of immunotherapy in castration-resistant prostate cancer (CRPC). *BJU International*, **2014**, 113, 367-76	5.6	3
85	Current status of pediatric donor en bloc kidney transplantation to young adult recipients. *Actas Urológicas Españolas*, **2013**, 37, 383-6	0.7	3
84	The role of prostate-specific antigen in light of new scientific evidence. *Actas Urológicas Españolas*, **2013**, 37, 324-9	0.7	3
83	25 THE SERUM TESTOSTERONE CASTRATION LEVEL WITH CLINICAL RELEVANCE. *European Urology Supplements*, **2007**, 6, 29	0.9	3
82	Analysis of Bone Alkaline Phosphatase as a Marker for the Diagnosis of Osteoporosis in Men under Androgen Ablation. *International Journal of Biological Markers*, **2003**, 18, 290-294	2.8	3
81	Bone alkaline phosphatase serum level predicts the response to antiandrogen withdrawal. *European Urology*, **2002**, 41, 257-61	10.2	3
80	Skeletal complications of ADT: disease burden and treatment options. *Asian Journal of Andrology*, **2012**, 14, 670-5	2.8	3
79	Assessing the Clinical Benefit of UBC Rapid in the Surveillance and Initial Diagnosis of Bladder Cancer. *Clinical Genitourinary Cancer*, **2020**, 18, 230-235	3.3	3
78	Current status of genetic urinary biomarkers for surveillance of non-muscle invasive bladder cancer: a systematic review. *BMC Urology*, **2020**, 20, 99	2.2	3
77	The role of negative magnetic resonance imaging: can we safely avoid biopsy in P.I.-R.A.D.S. 2 as in P.I.-R.A.D.S. 1?. *Scandinavian Journal of Urology*, **2019**, 53, 21-25	1.6	3
76	The role of prostate-specific antigen in light of new scientific evidence: An update in 2020. *Actas Urológicas Españolas*, **2021**, 45, 21-29	0.7	3

75	Definition of Castrate Resistant Prostate Cancer: New Insights.. *Biomedicines*, **2022**, 10,	4.8	3
74	A novel DNA-binding motif in prostate tumor overexpressed-1 (PTOV1) required for the expression of ALDH1A1 and CCNG2 in cancer cells. *Cancer Letters*, **2019**, 452, 158-167	9.9	2
73	Reversal Unilateral Ureteral Obstruction: A Mice Experimental Model. *Nephron*, **2019**, 142, 125-134	3.3	2
72	Behavior of total and free serum testosterone as a predictor for the risk of prostate cancer and its aggressiveness. *Actas Urológicas Españolas (English Edition)*, **2015**, 39, 573-581	0.1	2
71	Re: Bas W.G. van Rhijn, Theo H. van der Kwast, Sultan S. Alkhateeb, et al. A New and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 2012;61:378-84. *European Urology*, **2012**, 61, e53-4; author reply e55-6	10.2	2
70	Ultrasound-guided percutaneous radiofrequency ablation for treating small renal masses. *Actas Urológicas Españolas*, **2017**, 41, 497-503	0.7	2
69	Antihypertensive drugs and the risk of prostate cancer. *European Urology*, **2011**, 60, 1309-10	10.2	2
68	Behavior of Bone Alkaline Phosphatase (BAP) Determined with Immunoradiometric Assay in Metastatic Prostate Cancer. *International Journal of Biological Markers*, **1994**, 9, 145-145	2.8	2
67	Patient-derived AVATAR mouse models to predict prognosis in advanced renal cell carcinoma.. *Journal of Clinical Oncology*, **2016**, 34, 551-551	2.2	2
66	The Efficacy of Proclarix to Select Appropriate Candidates for Magnetic Resonance Imaging and Derived Prostate Biopsies in Men with Suspected Prostate Cancer.. *World Journal of Men?s Health*, **2021**,	6.8	2
65	Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy. *International Journal of Biological Markers*, **2005**, 20, 119-222	2.8	2
64	Value of percent free prostate-specific antigen for the prediction of pathological stage in men with clinically localized prostate cancer. *International Journal of Biological Markers*, **2002**, 17, 239-43	2.8	2
63	Early continence after radical prostatectomy: A systematic review. *Actas Urológicas Españolas*, **2019** , 43, 526-535	0.7	2
62	Effect of denosumab on prolonging bone-metastasis free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics.. *Journal of Clinical Oncology*, **2012**, 30, 4510-4510	2.2	2
61	Transcriptomic analysis of micropapillary high grade T1 urothelial bladder cancer. *Scientific Reports*, **2020**, 10, 20135	4.9	2
60	Measurement of serum testosterone during androgenic suppression in patients with prostate cancer: A systematic review. *Actas Urológicas Españolas (English Edition)*, **2016**, 40, 477-484	0.1	2
59	Are targeted prostate biopsies ready to replace systematic prostate biopsies?. *Actas Urológicas Españolas*, **2019**, 43, 573-578	0.7	2
58	Re: Lars Boesen, Nis Nørgaard, Vibeke Løgager, et al. Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7-10 Prostate Cancer in Biopsy-naïve Men. Eur Urol Oncol 2019;2:311-9. *European Urology Oncology*, **2020**, 3, 392-393	6.7	2

57	Multiple immunofluorescence assay identifies upregulation of Active □catenin in prostate cancer. *BMC Research Notes*, **2019**, 12, 68	2.3	1
56	Re: Frank-Jan H. Drost, Daniel Osses, Daan Nieboer, et al. Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis. Eur Urol 2020;77:78-94: Are Targeted Prostate Biopsies Enough in Men with a Previous Negative Biopsy?. *European Urology*, 2020, 77, e138-e139	10.2	1
55	Bone health in patients with prostate cancer. *Actas Urológicas Españolas*, **2014**, 38, 685-93	0.7	1
54	Sedentarism and overweight as risk factors for the detection of prostate cancer and its aggressiveness. *Actas Urológicas Españolas (English Edition)*, **2014**, 38, 232-237	0.1	1
53	Current significance of the finding of high grade prostatic intraepithelial neoplasia in the prostate biopsy. *Actas Urológicas Españolas (English Edition)*, **2014**, 38, 270-275	0.1	1
52	Native ureteropyelostomy in the treatment of obstructive uropathy in adult renal transplant. Experience and technical alternatives. *Actas Urológicas Españolas*, **2014**, 38, 552-6	0.7	1
51	Re: Magdalena G□tz, Jan Philipp Radtke, Gencay Hatiboglu, et al. The Value of Prostate-specific Antigen Density for Prostate Imaging-Reporting and Data System 3 Lesions on Multiparametric Magnetic Resonance Imaging: A Strategy to Avoid Unnecessary Prostate Biopsies. Eur Urol Focus 2021;7:325-31.. *European Urology Focus*, **2022**,	5.1	1
50	Improving the Early Detection of Clinically Significant Prostate Cancer in Men in the Challenging Prostate Imaging-Reporting and Data System 3 Category.. *European Urology Open Science*, **2022**, 37, 38-44	0.9	1
49	Effect of concurrent proton pump inhibitors (PPI) use in patients (pts) treated with immune checkpoint inhibitors (ICI) for metastatic urothelial carcinoma (mUC).. *Journal of Clinical Oncology*, **2020**, 38, 500-500	2.2	1
48	Serum Luteinizing Hormone Testing Can Identify Optimal Medical Castration. *European Urology Open Science*, **2020**, 19, 24-26	0.9	1
47	Are Multiparametric Magnetic Resonance Imaging and Guided Biopsies Needed in Men with Normal Digital Rectal Examination and Prostatic-specific Antigen >20 ng/ml?. *European Urology Oncology*, **2021**, 4, 334-335	6.7	1
46	The position of urethrovesical anastomosis after robotic radical prostatectomy assessed by MRI predicts early functional recovery: A cohort analyses from a randomized clinical trial. *European Journal of Radiology*, **2021**, 137, 109589	4.7	1
45	Comparison of standard vs. palliative management for bladder cancer in patients older than 85 years: multicenter study of 317 de novo tumors. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 40.e9-40.e15	2.8	1
44	Alternating Cystoscopy with Bladder EpiCheck□ in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model. *Bladder Cancer*, **2021**, 7, 307-315	1	1
43	Behavior of SelectMDx and Prostate-specific Antigen Density in the Challenging Scenario of Prostate Imaging-Reporting and Data System Category 3 Lesions. *European Urology*, **2021**, 81, 124-124	10.2	1
42	Prostate carcinoma staging: Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen **1996**, 78, 2374		1
41	Measurement of free PSA in the diagnosis and staging of prostate cancer **1997**, 71, 756		1
40	Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen. *Cancer*, **1996**, 78, 2374-8	6.4	1

39	Who with suspected prostate cancer can benefit from Proclarix after multiparametric magnetic resonance imaging?. *International Journal of Biological Markers*, **2022**, 3936155221081537	2.8	1
38	The Barcelona Predictive Model of Clinically Significant Prostate Cancer.. *Cancers*, **2022**, 14,	6.6	1
37	Proclarix, A New Biomarker for the Diagnosis of Clinically Significant Prostate Cancer: A Systematic Review.. *Molecular Diagnosis and Therapy*, **2022**, 26, 273	4.5	1
36	Re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol 2009;56:659-68. *European Urology*, **2010**, 57, e1; author reply e2-3	10.2	0
35	Multidisciplinary Consensus on the Prevention and Treatment of Osteoporosis and Fragility Fractures in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy.. *World Journal of Men?s Health*, **2022**, 40, 74-86	6.8	0
34	Association among the R.E.N.A.L. nephrometry score and clinical outcomes in patients with small renal masses treated with percutaneous contrast enhanced ultrasound radiofrequency ablation. *Central European Journal of Urology*, **2019**, 72, 92-99	0.9	0
33	Nuclear and cytosolic pS727-STAT3 levels correlate with overall survival of patients affected by clear cell renal cell carcinoma (ccRCC). *Scientific Reports*, **2021**, 11, 6957	4.9	0
32	Systematic review of renal carcinoma prognostic factors. *Actas Urol□gicas Espa□olas (English Edition)*, **2017**, 41, 215-225	0.1	
31	The role of STAT3 protein as a prognostic factor in the clear cell renal carcinoma. Systematic review. *Actas Urol□gicas Espa□olas (English Edition)*, **2019**, 43, 118-123	0.1	
30	Analysis of the nuclear expression of pSer727-STAT3 as a prognostic factor in patients with clear cell renal carcinoma. *Actas Urol□gicas Espa□olas (English Edition)*, **2020**, 44, 245-250	0.1	
29	Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry. *Actas Urol□gicas Espa□olas (English Edition)*, **2020**, 44, 156-163	0.1	
28	A systematic review of methods for quantifying serum testosterone in patients with prostate cancer who underwent castration. *Actas Urol□gicas Espa□olas (English Edition)*, **2018**, 42, 86-93	0.1	
27	Replay by authors: Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 571	2.8	
26	Metabolic syndrome in patients with prostate cancer undergoing androgen suppression. *Actas Urol□gicas Espa□olas (English Edition)*, **2014**, 38, 285-289	0.1	
25	The role of prostate-specific antigen in light of new scientific evidence. *Actas Urol□gicas Espa□olas (English Edition)*, **2013**, 37, 324-329	0.1	
24	Bone health in patients with prostate cancer. *Actas Urol□gicas Espa□olas (English Edition)*, **2014**, 38, 685-693	0.1	
23	Recommendations on the management of controversies in advanced castrate-resistant prostate cancer. *Actas Urol□gicas Espa□olas (English Edition)*, **2012**, 36, 569-577	0.1	
22	Loss of bone mass in patients with prostate cancer subjected to androgenic deprivation. *Actas Urol□gicas Espa□olas (English Edition)*, **2011**, 35, 232-239	0.1	

21	Re: Endo et al.: Anteroposterior dissection HoLEP: a modification to prevent transient stress urinary incontinence (Urology 2010;76:1451-1455). *Urology*, **2011**, 77, 255-6; author reply 256-7	1.6
20	Value of Percent Free Prostate-Specific Antigen for the Prediction of Pathological Stage in Men with Clinically Localized Prostate Cancer. *International Journal of Biological Markers*, **2002**, 17, 239-243	2.8
19	Impact of kidney and liver metabolism on serum prostate specific antigen levels. *International Journal of Biological Markers*, **1995**, 10, 236-237	2.8
18	The importance of appropriate castrate level measurements of serum testosterone in prostate cancer patients.. *Radiotherapy and Oncology*, **2022**,	5.3
17	Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry. *Actas Urológicas Españolas*, **2020**, 44, 156-163	0.7
16	Analysis of bone alkaline phosphatase as a marker for the diagnosis of osteoporosis in men under androgen ablation. *International Journal of Biological Markers*, **2003**, 18, 290-4	2.8
15	The role of previous radical local treatment (RLT) on the outcome of immune checkpoint inhibitors (ICI) in patients (pts) with metastatic urothelial carcinoma (mUC).. *Journal of Clinical Oncology*, **2020** , 38, 496-496	2.2
14	Analysis of the nuclear expression of pSer727-STAT3 as a prognostic factor in patients with clear cell renal carcinoma. *Actas Urológicas Españolas*, **2020**, 44, 245-250	0.7
13	Renal cell carcinoma avatar mouse models for the personalized cancer therapy era.. *Journal of Clinical Oncology*, **2015**, 33, e15627-e15627	2.2
12	C-MYC, HER2, and HER3 expression in localized prostate cancer (PC) treated with radical radiotherapy: Modulation by statins use and correlation with time to progression.. *Journal of Clinical Oncology*, **2013**, 31, e16045-e16045	2.2
11	Prediction of clinically significant prostate cancer after negative prostate biopsy: The current value of microscopic findings. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 432.e11-432.e19	2.8
10	Valor actual de los hallazgos histológicos de biopsias de próstata negativas en la predicción del riesgo futuro de cáncer de próstata clínicamente significativo. *Actas Urológicas Españolas*, **2021**, 45, 447-447	0.7
9	A comparative study of different surgical techniques for the management of distal ureter during laparoscopic radical nephroureterectomy. *Actas Urológicas Españolas*, **2019**, 43, 543-550	0.7
8	Re: Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer. *Journal of Urology*, **2021**, 205, 343-345	2.5
7	Use of an acellular collagen-elastin matrix to support bladder regeneration in a porcine model of peritoneocystoplasty. *Central European Journal of Urology*, **2018**, 71, 353-359	0.9
6	The current value of histological findings in negative prostate biopsies to predict the future risk of clinically significant prostate cancer. *Actas Urológicas Españolas (English Edition)*, **2021**, 45, 447-454	0.1
5	Reply to Nikolaos Kalampokis, Nikolaos Grivas, Markos Karavitakis, and Henk van der Poel's Letter to the Editor re: Aina Salazar, Lucas Regis, Jacques Planas, et al. A Randomised Controlled Trial to Assess the Benefit of Posterior Rhabdosphincter Reconstruction in Early Urinary Continence Recovery after Robot-assisted Radical Prostatectomy. Eur Urol Oncol. In press.	6.7
4	The role of prostate-specific antigen in light of new scientific evidence: An update in 2020. *Actas Urológicas Españolas (English Edition)*, **2021**, 45, 21-29	0.1

3	Application of One-Step Nucleic Acid Amplification (OSNA) in different cancer entities and usefulness in prostate cancer: a systematic review.. *BMC Cancer*, **2022**, 22, 357	4.8
2	Comparative Analysis of PSA Density and an MRI-Based Predictive Model to Improve the Selection of Candidates for Prostate Biopsy. *Cancers*, **2022**, 14, 2374	6.6
1	Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI. *Cancers*, **2022**, 14, 2702	6.6